Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Allan C. deCamp,Martin M. Corcoran,William J. Fulp,Jordan R. Willis,Christopher A. Cottrell,Daniel L. V. Bader,Oleksandr Kalyuzhniy,David J. Leggat,Kristen W. Cohen,Ollivier Hyrien,Sergey Menis,Greg Finak,Lamar Ballweber-Fleming,Abhinaya Srikanth,Jason R. Plyler,Farhad Rahaman,Angela Lombardo,Vincent Philiponis,Rachael E. Whaley,Aaron Seese,Joshua Brand,Alexis M. Ruppel,Wesley Hoyland,Celia R. Mahoney,Alberto Cagigi,Alison Taylor,David M. Brown,David R. Ambrozak,Troy Sincomb,Tina-Marie Mullen,Janine Maenza,Orpheus Kolokythas,Nadia Khati,Jeffrey Bethony,Mario Roederer,David Diemert,Richard A. Koup,Dagna S. Laufer,Juliana M. McElrath,Adrian B. McDermott,Gunilla B. Karlsson Hedestam,William R. Schief
DOI: https://doi.org/10.1038/s41541-024-00811-5
2024-03-12
npj Vaccines
Abstract:Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targeting immunogen, higher frequencies of vaccine-induced VRC01-class bnAb-precursor B cells were observed in the high dose compared to the low dose group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification of IGHV1-2 allele usage and B cell frequencies in the naive repertoire for each trial participant, and antibody affinity analyses, we found that the difference between dose groups in VRC01-class response frequency was best explained by IGHV1-2 genotype rather than dose and was most likely due to differences in IGHV1-2 B cell frequencies for different genotypes. The results demonstrate the need to define population-level immunoglobulin allelic variations when designing germline-targeting immunogens and evaluating them in clinical trials.
immunology,medicine, research & experimental